(NOVT) Novanta - Overview
Sector: Technology | Industry: Scientific & Technical Instruments | Exchange: NASDAQ (USA) | Market Cap: 5.687m USD | Total Return: 28.2% in 12m
Avg Turnover: 64.7M
EPS Trend: -20.2%
Qual. Beats: -1
Rev. Trend: 96.5%
Qual. Beats: 4
Warnings
P/E ratio 114.9
Choppy
Tailwinds
No distinct edge detected
Novanta Inc. (NOVT) is a technology provider specializing in precision medicine, advanced manufacturing, and medical robotics. Headquartered in Bedford, Massachusetts, the company operates through two primary segments: Automation Enabling Technologies and Medical Solutions. Its portfolio includes laser beam steering, robotic motion control, medical insufflators, and integrated operating room technologies.
The company operates within the Electronic Equipment & Instruments sub-industry, where revenue is often driven by the increasing integration of automation in surgical procedures and high-precision industrial lithography. Novanta’s business model relies on being an original equipment manufacturer (OEM) partner, embedding its proprietary optical and motion components into the complex systems of larger healthcare and industrial corporations.
Investors can further analyze these segment performance metrics and valuation trends on ValueRay. Founded in 1968 as GSI Group, the company rebranded to Novanta in 2016 to reflect its expanded focus on the convergence of medical and industrial automation technologies.
- High-growth medical robotics adoption accelerates long-term revenue in the Medical Solutions segment
- Expansion of precision laser manufacturing drives demand within advanced industrial automation markets
- Supply chain stabilization and inventory normalization impact short-term operational margin performance
- Increasing R&D investment in minimally invasive surgery tools dictates future market share gains
| Net Income: 53.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -6.54 > 1.0 |
| NWC/Revenue: 56.32% < 20% (prev 27.80%; Δ 28.53% < -1%) |
| CFO/TA 0.05 > 3% & CFO 82.7m > Net Income 53.7m |
| Net Debt (-48.4m) to EBITDA (179.4m): -0.27 < 3 |
| Current Ratio: 3.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.2m) vs 12m ago 13.92% < -2% |
| Gross Margin: 41.48% > 18% (prev 0.44%; Δ 4.10k% > 0.5%) |
| Asset Turnover: 63.11% > 50% (prev 68.69%; Δ -5.58% > 0%) |
| Interest Coverage Ratio: 6.61 > 6 (EBITDA TTM 179.4m / Interest Expense TTM 17.7m) |
| A: 0.31 (Total Current Assets 786.8m - Total Current Liabilities 220.8m) / Total Assets 1.80b |
| B: 0.19 (Retained Earnings 342.5m / Total Assets 1.80b) |
| C: 0.07 (EBIT TTM 116.8m / Avg Total Assets 1.59b) |
| D: 1.55 (Book Value of Equity 754.6m / Total Liabilities 488.0m) |
| Altman-Z'' = 4.80 = AA |
| DSRI: 1.00 (Receivables 173.9m/164.2m, Revenue 1.00b/951.7m) |
| GMI: 1.06 (GM 41.48% / 44.12%) |
| AQI: 0.83 (AQ_t 0.48 / AQ_t-1 0.58) |
| SGI: 1.06 (Revenue 1.00b / 951.7m) |
| TATA: -0.02 (NI 53.7m - CFO 82.7m) / TA 1.80b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of May 31, 2026, the stock is trading at USD 159.33 with a total of 761,238 shares traded.
Over the past week, the price has changed by +2.87%,
over one month by +31.80%,
over three months by +18.52% and
over the past year by +28.16%.
Novanta has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NOVT.
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 171.5 | 7.6% |
P/E Trailing = 114.8921
P/E Forward = 8.3893
P/S = 5.6593
P/B = 4.338
P/EG = 2.11
Revenue TTM = 1.00b USD
EBIT TTM = 116.8m USD
EBITDA TTM = 179.4m USD
Long Term Debt = 201.0m USD (from longTermDebt, last quarter)
Short Term Debt = 51.0m USD (from shortTermDebt, last quarter)
Debt = 340.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 49.1m
Net Debt = -48.4m USD (calculated: Debt 340.4m - CCE 388.8m)
Enterprise Value = 5.64b USD (5.69b + Debt 340.4m - CCE 388.8m)
Interest Coverage Ratio = 6.61 (Ebit TTM 116.8m / Interest Expense TTM 17.7m)
EV/FCF = 83.91x (Enterprise Value 5.64b / FCF TTM 67.2m)
FCF Yield = 1.19% (FCF TTM 67.2m / Enterprise Value 5.64b)
FCF Margin = 6.69% (FCF TTM 67.2m / Revenue TTM 1.00b)
Net Margin = 5.35% (Net Income TTM 53.7m / Revenue TTM 1.00b)
Gross Margin = 41.48% ((Revenue TTM 1.00b - Cost of Revenue TTM 588.1m) / Revenue TTM)
Gross Margin QoQ = 41.83% (prev 40.70%)
Tobins Q-Ratio = 3.13 (Enterprise Value 5.64b / Total Assets 1.80b)
Interest Expense / Debt = 5.19% (Interest Expense 17.7m / Debt 340.4m)
Taxrate = 19.94% (5.25m / 26.4m)
NOPAT = 93.5m (EBIT 116.8m * (1 - 19.94%))
Current Ratio = 3.56 (Total Current Assets 786.8m / Total Current Liabilities 220.8m)
Debt / Equity = 0.26 (Debt 340.4m / totalStockholderEquity, last quarter 1.31b)
Debt / EBITDA = -0.27 (Net Debt -48.4m / EBITDA 179.4m)
Debt / FCF = -0.72 (Net Debt -48.4m / FCF TTM 67.2m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.37% (Net Income 53.7m / Total Assets 1.80b)
RoE = 5.08% (Net Income TTM 53.7m / Total Stockholder Equity 1.06b)
RoCE = 9.29% (EBIT 116.8m / Capital Employed (Equity 1.06b + L.T.Debt 201.0m))
RoIC = 7.54% (NOPAT 93.5m / Invested Capital 1.24b)
WACC = 10.42% (E(5.69b)/V(6.03b) * Re(10.80%) + D(340.4m)/V(6.03b) * Rd(5.19%) * (1-Tc(0.20)))
Discount Rate = 10.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 6.03%
[DCF] Terminal Value 65.76% ; FCFF base≈97.3m ; Y1≈85.3m ; Y5≈68.9m
[DCF] Fair Price = 24.54 (EV 825.5m - Net Debt -48.4m = Equity 873.9m / Shares 35.6m; r=10.42% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -20.19 | EPS CAGR: -0.55% | SUE: -4.0 | # QB: -1
Revenue Correlation: 96.50 | Revenue CAGR: 4.82% | SUE: 2.28 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.83 | Chg30d=-3.49% | Revisions=-14% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.94 | Chg30d=+1.81% | Revisions=+14% | Analysts=3
EPS current Year (2026-12-31): EPS=3.59 | Chg30d=+0.75% | Revisions=+14% | GrowthEPS=+9.1% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=4.14 | Chg30d=+2.39% | Revisions=+33% | GrowthEPS=+15.4% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: +33%